Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I liked the slow and steady action! What a buy at $6
I would think Novocure is a buyout candidate imo
Great day today. Very nice earnings. Looking for $25
Surprised there is less action on this board. Steady three month growth. Still buying more 3 months later no stop in sight
JMP Securities Reiterates Novocure Ltd (NVCR) Outperform $34.00
Novocure Ltd (NVCR) Given Outperform Rating at JMP Securities
April 4th, 2017 • 0 comments • Filed Under • by ABMN Staff
inShare
Novocure logoNovocure Ltd (NASDAQ:NVCR)‘s stock had its “outperform” rating reaffirmed by analysts at JMP Securities in a research note issued on Tuesday. They presently have a $34.00 price objective on the stock. JMP Securities’ price target would suggest a potential upside of 206.31% from the stock’s current price.
Several other equities analysts have also recently issued reports on NVCR. Zacks Investment Research cut shares of Novocure from a “buy” rating to a “hold” rating in a research report on Friday, March 17th. Wedbush restated an “outperform” rating and issued a $20.00 price target on shares of Novocure in a research report on Wednesday, December 21st. JPMorgan Chase & Co. restated a “buy” rating and issued a $14.00 price target on shares of Novocure in a research report on Sunday, February 26th. Wells Fargo & Co cut shares of Novocure from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 11th. Finally, Aegis restated a “buy” rating and issued a $14.00 price target on shares of Novocure in a research report on Tuesday, March 28th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock.
10.85 LOD A/H
MEANWHILE Cyclacel Pharmaceuticals IS STEALING THE SHOW A/H
IM SHOCKED NLOD $11.00
VERY SHOCKED
SELLERS ARE STRONG
WHATS NEXT A/H OFFERING
Apr-03-17 01:06PM Here's Why NovoCure Ltd. Is Skyrocketing Today at Motley Fool +43.21%
12:22PM Why Bulls Are Piling Into Novocure Ltd (NVCR) Today at Insider Monkey
11:40AM Novocure Glioblastoma Drug Offers Survival Benefits at Investopedia
11:29AM Novocure Ltd. stock surges nearly 50% after positive late-stage trial results in brain cancer at MarketWatch
11:17AM Novocure shares skyrocket 50% after positive trial results at CNBC
09:29AM Biotech Movers: Novocure, United Therapeutics, Kite Pharma
09:05AM Why NovoCure Shares Are Skyrocketing
http://finviz.com/quote.ashx?t=NVCR&ty=c&ta=1&p=d
Motley Fool says today is only the begining.
Here's Why NovoCure Ltd. Is Skyrocketing Today
Now what
While NovoCure has consistently posted triple-digit top-line growth over the last few quarters, its stock has been a dreadful long-term performer. In fact, it has badly trailed the medical device industry in general as measured by the iShares US Medical Devices ETF (NYSEMKT:IHI) since its October 2015 IPO.
Thankfully, the data from all of these clinical trials suggest that Optune holds the potential to have a transformative impact on the way that we treat numerous types of cancers. Given that tens of thousands of patients die from ovarian, pancreatic, solid tumor, and brain cancer each year in the U.S. alone, the potential growth runway for Optune continues to look massive. For perspective, only 1,091 patients worldwide were actively using Optune as of the end of 2016.
Looking ahead, the uplifting data from the EF-14 trial should make it easier for the company to convince providers, patients, and insurers to use and cover Optune. That would allow the company's torrid top-line growth rate to continue. Meanwhile, the data from the Panova, Stellar, and Innovate trials suggest that NovoCure's plans to expand Optune's labeling to other types of cancer could also work out. If true, then it is possible that today's big jump could just be the start of a profitable long-term run.
It'll still close in the $14s IMO. You know MMs like to cause a Noon Swoon panic to pick up shares before EOD run.
DOWN SHE GOES 11.30'S
Remember some were able to pick up shares in the $6 range. Profit taking
Market Makers holding this down. tons of thousands slapping the ask over and over and the tiny size not changing. MMs doing their best to control this pop to get themselves net long. We'll close in the $14s minimum.
UGH BACK TO 11.80'S
SOBZZZ
NVCR 12.65'S GOING AGAIN
VOLUME IS KEY HERE.... NEEDS MORE PRESSURE
Here's an interesting thought....I see from the board you have been here a while, but in 30-minutes of reading here is what I've found.....TTF (the technology used by NVCR) has not been approved by the FDA yet "TTFields are not approved for the treatment of ovarian cancer by the U.S. Food and Drug Administration. The safety and effectiveness of TTFields therapy for ovarian cancer has not been established"
However with 3 now consecutive successful Phase 2 and Phase 3 positive result studies done with this technology/device....can you imagine what NVCR would be if the FDA finally approved the TTF technology for treatments? They now have the technology and data to put pressure on the FDA for TTF Treatment approvals it looks like.
$NVCR unlike a lot of under $10 pharms is not a one-trick pony per say....they have several phase studies in the pipeline and the brain cancer treatment phase 3 study/results yesterday were very positive and encouraging and will gain support now as the news articles state.
I would NOT be surprised now after the results of the 3 studies that something very soon gets Fast Tracked by the FDA.
JMO
As of now it looks to have settled and has made 3 consecutive higher lows on the 30-minute....shorts under $12 were playing a dangerous game as I see on twitter some were saying short even @ $11.80. Profit takers should be out let's see if this pushes again.
key point: $12.50 this is where it bounced to 3x but couldn't get back over it since dipping below it after open. Break $12.50 and sustain it and it will be in good shape the rest of the day and tomorrow PM/Market open.
Just looking for higher high and higher lows!! $20 will be in the future with patience IMO
Wow 120K block @ $12....that will kill just about any type of run...Let's chip away!
The news is good for more than just an hour trade, people loading up @ $11-$12 here on huge record daily volume....there could be more updates coming IMO as the conference is still going on and they don't present until tomorrow I believe.
Wow my $12 opening target was way to low!
Do you really think it can run to $18??
$14 'S LOOK LIKE SOME RESIST IF BREAKS THRU NP, SHOULD BE NICE TO $16-18
NVCR
We may see $16.+ today. also still thinking we may run to $25. sometime this week. See how it plays out.
13.80'S SO FAR
NVCR
Might hit $14s before open strong recovery off the $12.35 dip.
PM Shares switching hands @ $12s and healthy pullback from $13.35 to $12.35.
Congrats they payed off looks like 13$s going p/m
We may have a runner! Watching at open for trend!
13.15x13.20 l;ol
NVCR GOOOOOO!
Wow amazing! This will at least double tomorrow!
CBS News Health Headline $NVCR
http://www.cbsnews.com/news/cancer-therapy-fights-brain-tumors-optune-novocure/
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
559
|
Created
|
10/07/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |